annual meeting program - American Society of Clinical Oncology

SATURDAY
Saturday, June 5, 2010
Brd. 3F Comparison of 21-gene recurrence score (RS) in African-American (AA) and
Caucasian (C) patients with hormone receptor (HR)-positive early-stage
breast cancer. (Abstract #557)
K. M. Davis, A. B. Zelnak, S. Murali, D. Senior-Crosby, S. Gabram-Mendola,
G. W. Carlson, W. C. Wood, C. Wang, T. M. Styblo, R. O’Regan
Brd. 3G Effect of dose-dependent interaction between tamoxifen and antidepressants
on patient adherence in breast cancer patients. (Abstract #558)
F. W. Frueh, J. Tinnirello, M. Khalid, N. J. Markward, M. Subar, R. E. Aubert,
R. S. Epstein
Brd. 3H BACH: A randomized phase II trial of doxorubicin-cyclophosphamide (AC)
versus pegylated liposomal doxorubicin (PLD)-cyclophosphamidetrastuzumab
(CCH) followed by paclitaxel-trastuzumab (TH) as adjuvant
therapy for HER2-positive breast cancer (BC)—Cardiac safety analysis.
(Abstract #559)
D. Rayson, T. Suter, S. van der Vegt, A. Lluch, J. Van Den Bosch, G. Lopez-
Vivanco, A. M. Van Gent, H. Wildiers, L. Provencher, D. Richel
Brd. 4A Gene signature of metformin actions on primary breast cancer within a
window of opportunity randomized clinical trial. (Abstract #560)
S. M. Hadad, J. A. Dewar, E. Elseedawy, L. Jordan, C. Purdie, S. E. Bray,
A. M. Thompson
Brd. 4B Evaluation of the 70-gene prognosis MammaPrint signature for the
prediction of prognosis of breast cancer independently from histologic
grade. (Abstract #561)
M. Knauer, E. J. Rutgers, S. Mook, J. Wesseling, L. J. van ’t Veer
Brd. 4C Obesity, patient characteristics, and TIMP-1: Effects on non-bone RFS in
NCIC CTG MA.14. (Abstract #562)
J. W. Chapman, S. M. Ali, A. Lipton, K. Leitzel, K. I. Pritchard, L. Han,
W. P. Carney, C. F. Wilson, L. E. Shepherd, M. N. Pollak
Brd. 4D Predictive value of neoadjuvant chemotherapy failure in breast cancer using
FDG-PET after the first course. (Abstract #563)
H. Kolesnikov-Gauthier, L. Vanlemmens, M. Baranzelli, P. Carpentier, S. Habbas,
P. Vennin, V. Servent, C. Fournier, J. Bonneterre
Brd. 4E Comparison of first-course PET scan against fourth-course MRI for early
detection of poor responders to neoadjuvant chemotherapy (NAC) for breast
cancer (BC). (Abstract #564)
M. Cotto, J. Toro, V. Carlo, R. Vaquer, O. A. Pavia, M. Bruno, E. Rivera,
M. M. Echenique, V. Negron, F. Cabanillas
Brd. 4F Safety and tolerability of lapatinib ditosylate given concurrently with
docetaxel, carboplatin, and trastuzumab (TCHL) as part of adjuvant therapy
for patients with HER2� breast cancer: Pilot data from the North Central
Cancer Treatment Group Trial N083E. (Abstract #565)
C. Bueno Hume, A. Moreno-Aspitia, D. W. Hillman, A. T. Perez, B. Chen,
R. B. Jenkins, A. C. Dueck, D. B. Johnson, R. L. Carolla, E. A. Perez
Brd. 4G Gene expression profile testing for breast cancer: Patterns and predictors of
use and impact on chemotherapy. (Abstract #566)
M. J. Hassett, J. C. Niland, M. E. Hughes, R. L. Theriault, D. W. Blayney, Y. Wong,
C. Hudis, P. K. Marcom, C. Laronga, J. C. Weeks
Brd. 4H Five-year results of preoperative concurrent paclitaxel with radiation in
locally advanced breast cancer (LABC). (Abstract #567)
S. Formenti, S. Adams, A. B. Chakravarthy, S. C. Lymberis, D. V. Spicer,
J. A. Bauer, M. Volm, D. Roses, J. D. Goldberg, J. A. Pietenpol
148